The overall aim of CCIT-DK is to significantly improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT-DK has a focus on development of immunological treatment of cancer, and has a research profile based on equally weighted experimental and clinical projects with a tight interconnection. During the last few years we have carried out numerous clinical trials based on a direct translation of the discoveries from the laboratory. CCIT-DK facilitates quick clinical implementation of new immunotherapies e.g. anti-CTLA4 therapy for melanoma which was implemented in the clinic only 3 weeks after publication of significant phase III data. And as the first and one of only 3 centres in Europe we established the advanced T-cell therapy for metastatic melanoma in the clinic. CCIT-DK provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic cellular products.
CCIT-DK has a total of around 50 employees, including scientific and technical staff. We are focused on creating an international environment and have a long list of clinical and scientific collaborators illustrating the strong standing in field. Finally, CCIT-DK contribute substantially to the education of next generation scientists and clinicians in the field.
National Center for Cancer Immune Therapy (CCIT-DK)
In 2017 CCIT was appointed national research and competence center for immunotherapy - CCIT-Denmark (CCIT-DK) based on a grant from the Danish Cancer Society. CCIT has built up an extensive clinical and experimental track record, a broad cooperation at local, national, and international level, and has established itself as one of the leading European centers in cancer immunotherapy. As an embedded center in the Danish Comprehensive Cancer Center, CCIT-DK has assumed the role of national driving force for continued development of cancer immunotherapy research in Denmark. Accordingly, CCIT-DK has founded the national research network IMMUNONET, and the Clinical-Academic Group in Cancer Immunotherapy, CAGci, in the Capital Region of Denmark.
CCIT-DK has as an important goal to increase the number and availability of clinical immunotherapy trials to the benefit of Danish cancer patients. Further, CCIT-DK will increase experimental, translational, and clinical research collaboration in cancer immunology and immunotherapy across the country and facilitate knowledge building, education, communication, and patient involvement.